Edrophonium Chloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	IV	0.1-0.2 mg/kg (diagnostic test); 0.5-1 mg/kg (reversal of neuromuscular blockade)	Single dose for diagnostic test; for reversal, administer after atropine (0.02-0.04 mg/kg IV)	Duration: Single administration; effects last 5-15 minutes Notes: For Tensilon test, administer a small test dose (0.1 mg) IV and observe for 30 seconds; if no response, give the remainder. Have atropine available for bradycardia.
Cat	IV	0.1-0.2 mg/kg (diagnostic test); 0.5-1 mg/kg (reversal of neuromuscular blockade)	Single dose for diagnostic test; for reversal, administer after atropine (0.02-0.04 mg/kg IV)	Duration: Single administration; effects last 5-15 minutes Notes: Same as dog; use with caution in cats with cardiac disease.
Horse	IV	0.05-0.1 mg/kg (diagnostic test); 0.5-1 mg/kg (reversal of neuromuscular blockade)	Single dose	Duration: Single administration Notes: Monitor for bradycardia and bronchospasm; atropine should be available.
Cattle	IV	0.1 mg/kg (experimental)	Single dose	Duration: Single administration Notes: Not commonly used; use with caution.
Small Ruminants	IV	0.1 mg/kg (experimental)	Single dose	Duration: Single administration Notes: Not commonly used; use with caution.
Rabbit	IV	0.1-0.2 mg/kg (research)	Single dose	Duration: Single administration Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Diagnostic agent for myasthenia gravis
Reversal agent for non-depolarizing neuromuscular blocking drugs
Treatment of atrial tachycardia (as a vagal stimulant)

Dog (Canine)

Diagnosis of myasthenia gravis (Tensilon test)
Reversal of non-depolarizing neuromuscular blockade (e.g., atracurium, vecuronium)
Treatment of supraventricular tachycardia (as a vagomimetic agent)

Cat (Feline)

Diagnosis of myasthenia gravis (Tensilon test)
Reversal of non-depolarizing neuromuscular blockade

Horse (Equine)

Diagnosis of myasthenia gravis (rarely used)
Reversal of non-depolarizing neuromuscular blockade

Pharmacology & Mechanism of Action

Drug Class: Anticholinesterase (acetylcholinesterase inhibitor) | Pharmacological Group: Quaternary ammonium compound

Mechanism of Action: Edrophonium chloride is a short-acting, reversible acetylcholinesterase inhibitor. It binds reversibly to the anionic site of acetylcholinesterase, preventing the hydrolysis of acetylcholine. This results in an accumulation of acetylcholine at cholinergic synapses, enhancing cholinergic transmission at both muscarinic and nicotinic receptors. Its rapid onset and short duration of action make it useful for diagnostic purposes (e.g., myasthenia gravis) and for reversing the effects of non-depolarizing neuromuscular blocking agents.

Pharmacodynamics: Edrophonium increases the concentration of acetylcholine at the neuromuscular junction, leading to enhanced muscle contraction. It also stimulates muscarinic receptors, causing bradycardia, increased salivation, lacrimation, bronchial secretions, and gastrointestinal motility. The drug's effects are rapid in onset (30-60 seconds after IV administration) and short-lived (5-15 minutes). It is less potent than neostigmine but has a faster onset and shorter duration.

⚡ Pharmacokinetics Summary

Absorption: Edrophonium is poorly absorbed after oral administration; therefore, it is typically administered parenterally (IV or IM). After IV administration, the onset of action is within 30-60 seconds.

Distribution: As a quaternary ammonium compound, edrophonium is highly ionized and poorly lipid-soluble, limiting its distribution across the blood-brain barrier and into the central nervous system. It distributes mainly in the extracellular fluid.

Metabolism: Edrophonium is minimally metabolized; it is primarily excreted unchanged by the kidneys.

Excretion: The drug is excreted primarily in the urine via glomerular filtration and tubular secretion. The elimination half-life is approximately 1-2 hours in humans, but in animals it is short due to rapid renal clearance.

Half-Life: Approximately 1-2 hours in dogs and cats; shorter in horses (about 0.5-1 hour).

Bioavailability: Oral bioavailability is negligible; parenteral administration is required for clinical effect.

Protein Binding: Low protein binding (less than 10%).

Available Formulations & Strengths

Injectable Solution 10 mg/mL (1 mL ampules) (IV, IM)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to edrophonium or any component
Mechanical intestinal or urinary obstruction
Known cholinergic crisis (in myasthenia gravis patients)
Concurrent use of depolarizing neuromuscular blockers (e.g., succinylcholine) may cause prolonged paralysis

Warnings & Clinical Precautions:

Use with extreme caution in animals with asthma, cardiac arrhythmias, or bradycardia
Atropine should be readily available to counteract severe muscarinic effects
In myasthenia gravis, differentiate between myasthenic crisis (under-treatment) and cholinergic crisis (over-treatment) before administration
May cause bronchoconstriction in animals with reactive airway disease
Use with caution in animals with renal impairment, as excretion may be reduced
Not for oral administration due to poor absorption

Adverse Effects & Reactions

Common:

Bradycardia
Salivation
Lacrimation
Bronchial secretions
Gastrointestinal hypermotility (diarrhea, vomiting)
Muscle fasciculations

Serious / Severe:

Severe bradycardia or cardiac arrest
Bronchospasm
Respiratory depression or paralysis (due to overstimulation of nicotinic receptors)
Cholinergic crisis (muscle weakness, respiratory failure)

Rare:

Hypersensitivity reactions
Seizures (at high doses)

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Atropine	Atropine antagonizes the muscarinic effects of edrophonium, preventing bradycardia and excessive secretions.	Moderate
Succinylcholine	Edrophonium may prolong the effects of succinylcholine by inhibiting its metabolism.	High
Aminoglycoside antibiotics (e.g., gentamicin)	May antagonize the effects of edrophonium, reducing its ability to reverse neuromuscular blockade.	Moderate
Beta-blockers (e.g., propranolol)	May increase the risk of bradycardia and hypotension.	Moderate
Digoxin	May increase the risk of bradyarrhythmias.	Moderate
Corticosteroids	May reduce the effectiveness of edrophonium in myasthenia gravis.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Excessive salivation
Lacrimation
Bradycardia
Hypotension
Muscle fasciculations
Weakness
Respiratory paralysis
Seizures

Emergency Treatment Protocol: Immediately discontinue the drug. Administer atropine sulfate (0.02-0.05 mg/kg IV) to counteract muscarinic effects. Provide supportive care including oxygen, mechanical ventilation if respiratory failure occurs, and fluid therapy for hypotension. Monitor cardiac function and electrolyte balance. In severe cases, pralidoxime (2-PAM) may be considered, but its efficacy is limited for quaternary ammonium compounds.

Food Animal Withdrawal Times

Not approved for food animals; withdrawal times not established. Use in food animals is off-label and requires veterinary oversight; consult regulatory guidelines.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (15-30°C)

Handling & Special Conditions: Protect from freezing. Keep in tightly closed container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for human use; not specifically approved for veterinary use, but may be used off-label in animals.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with a valid veterinary-client-patient relationship, but withdrawal times must be extended and residues must be avoided. Not approved for food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Edrophonium chloride is primarily used as a diagnostic agent for myasthenia gravis (Tensilon test) and as a reversal agent for non-depolarizing neuromuscular blockers. Its rapid onset and short duration make it ideal for diagnostic purposes. Always have atropine available to manage severe muscarinic effects. In myasthenia gravis, the test should be performed with caution, as it can precipitate a cholinergic crisis. For reversal of neuromuscular blockade, edrophonium is often combined with atropine to prevent bradycardia. Due to its short duration, it may not be suitable for prolonged reversal; neostigmine may be preferred in some cases. Use with caution in animals with cardiac disease, asthma, or renal impairment. Not recommended for oral use.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)